Over 1400 Antibacterial Drugs Are Currently in Active Development, States GBI Research in Its Discounted Study Available at MarketPublishers.com

02 May 2017 • by Natalie Aster

LONDON – Currently, more than 1400 antibacterial drug products are in active development, with most drugs being small molecules. The position of vaccines is also deeply entrenched within the marketplace, and they account for close to 25% of the pipeline.

To date, drugs utilised in the prophylaxis of bacterial infections are generally vaccines which aid in training the body’s immune system to get over bacterial infections caused by particular bacterial strains. Nevertheless, a number of prophylactic monoclonal antibodies (mAbs) are currently in the pipeline and could possibly have a bearing on the market in the short run.

Drugs used to treat various bacterial infections are more diverse to a certain degree. Most typical of them are B-lactam antibiotics, like penicillin, and protein-synthesis inhibitors. Still, bacterial resistance has decreased the efficacy of a host of these drugs. Thus, the pipeline encompasses a variety of new-generation protein synthesis inhibitors and B-lactam/B-lactamase inhibitor combinations, which are active against currently hard-to-treat strains of bacteria.

Comprehensive report “Antibacterial Therapies Drug Development Pipeline Review, 2017” elaborated by GBI Research provides an all-round, detailed analysis of the marketplace, focusing on covering the pipeline development for methicillin-resistant staphylococcus aureus (MRSA), pneumonia and tuberculosis, from the stage of discovery up to the pre-registration stage.

The study provides a granular examination of the products by the phase of development, molecular target, RoA, MoA and molecule type. The publication offers a complete listing of all the products in development, alongside shedding light on dormant and discontinued projects. Furthermore, the report presents an all-encompassing overview of the dominant players active in respective product development, and limelights latest updates and press releases pertaining to this area.

More topical market reports by this publisher can be found at GBI Research page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com